Kamada (NASDAQ:KMDA) Earns Buy Rating from Analysts at StockNews.com

Research analysts at StockNews.com assumed coverage on shares of Kamada (NASDAQ:KMDA – Get Rating) in a report released on Tuesday. The firm set a “buy” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and issued a $11.00 target price on shares of Kamada in a research note on Thursday, March 16th.

Kamada Stock Performance

Shares of Kamada stock opened at $4.86 on Tuesday. The business’s fifty day simple moving average is $4.62 and its 200 day simple moving average is $4.50. The firm has a market capitalization of $217.83 million, a P/E ratio of -97.18 and a beta of 0.99. Kamada has a 12 month low of $3.72 and a 12 month high of $5.43. The company has a current ratio of 1.84, a quick ratio of 0.93 and a debt-to-equity ratio of 0.07.

Kamada (NASDAQ:KMDA – Get Rating) last issued its quarterly earnings results on Wednesday, March 15th. The biotechnology company reported $0.11 EPS for the quarter, topping analysts’ consensus estimates of $0.07 by $0.04. The business had revenue of $45.44 million for the quarter, compared to analyst estimates of $44.64 million. Kamada had a positive return on equity of 6.12% and a negative net margin of 1.79%. As a group, analysts anticipate that Kamada will post 0.12 EPS for the current year.

Hedge Funds Weigh In On Kamada

Several hedge funds have recently made changes to their positions in the stock. Phoenix Holdings Ltd. grew its position in shares of Kamada by 2.2% in the fourth quarter. Phoenix Holdings Ltd. now owns 2,105,523 shares of the biotechnology company’s stock valued at $8,443,000 after purchasing an additional 45,612 shares in the last quarter. Altshuler Shaham Ltd grew its position in shares of Kamada by 7.2% in the third quarter. Altshuler Shaham Ltd now owns 919,697 shares of the biotechnology company’s stock valued at $4,630,000 after purchasing an additional 61,703 shares in the last quarter. Vanguard Group Inc. grew its position in Kamada by 7.3% during the third quarter. Vanguard Group Inc. now owns 864,789 shares of the biotechnology company’s stock worth $3,900,000 after buying an additional 58,705 shares in the last quarter. Wells Fargo & Company MN grew its position in Kamada by 4.5% during the fourth quarter. Wells Fargo & Company MN now owns 513,876 shares of the biotechnology company’s stock worth $2,000,000 after buying an additional 22,013 shares in the last quarter. Finally, Arete Wealth Advisors LLC purchased a new position in Kamada during the fourth quarter worth about $949,970,200,000. 15.29% of the stock is currently owned by hedge funds and other institutional investors.

Kamada Company Profile

(Get Rating)

Kamada Ltd. is a biopharmaceutical company, which focuses on specialty plasma-derived therapeutic. It operates through the Proprietary Products and Distribution segments. The Proprietary Products segment covers the development, manufacture, and sale of plasma-derived protein therapeutics products. The Distribution segment covers the drug products in Israel, which are manufactured by third parties.